TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03167437: An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 35 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT03167437 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03167437 Rescue Dossier →